Latest news with #Servier
Business Wire
31-07-2025
- Business
- Business Wire
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: "To date, it remains impossible to raise funds on Euronext for a biotechnology company that needs to conduct clinical proof-of-concept trials. As a result, our hopes for revenue and therefore cash availability rest primarily on discussions with potential buyers of our assets. The various cost-cutting measures we have taken since the beginning of this year are enabling us to continue these discussions over time, and the last quarter will be crucial in this regard." Karine LIGNEL, Managing Director and COO of Oncodesign Precision Medicine adds: "In a very difficult financial environment, we have taken management decisions that have enabled us to significantly reduce our expenses and thus extend our cash flow horizon as much as possible. We have also set up an equity financing line to deal with market uncertainties. Nevertheless, the situation remains complicated, and we are making every effort to secure a partnership for one of our assets." Key financial data A cost reduction program was implemented in the first half of 2025: Negotiations were held with the banks and BPI that granted the loan, resulting in a six-month deferral of principal repayments starting in April 2025 Expenses were reduced through The layoff of five employees in early 2025 A 50% reduction in the compensation of non-salaried corporate officers A freeze on salaries and bonus payments for the 2024 fiscal year A reduction in spending on non-priority programs. In terms of cash flow, rather than from an accounting perspective, this results in a reduction in payroll costs of €242k in the first half of 2025 and a projected reduction of €440k in the second half of this year. The reduction in expenditure is particularly significant for the item 'subcontracting and fees,' which will fall from €2,900k in the first half of 2024 to €1,773k in the first half of 2025. R&D expenses amounted to €1.74 million in the first half of 2025, compared with €3.61 million in the same period last year, as the company focused its efforts on the clinical development of OPM-101. Reintegration, in close collaboration with Servier, of all OPM-201 data and product stocks The most significant financial item in the first half of 2025 is the reintegration, as provided for in the partnership agreement, of the stock of OPM-201 GMP material produced by Servier. As this reintegration is being carried out without financial competing, OPM has called upon an external expert to determine fair value for these stocks. This expert carried out three different valuations to arrive at this fair value. A summary of these valuations is shown in the table below: The expert concluded that the fair value of these inventories falls within a range of €13 million to €16.2 million. OPM used the lower end of this range. OPM's revenue for the first half of 2025 was €0.1 million, the same as in the first half of 2024. Other income mainly consists of subsidies amounting to €0.3 million and €0.3 million in provision reversals. OPM's financial result was (€0.26) million, compared with (€0.1) million in the same period last year, mainly due to interest on outstanding loans and financial income from cash investments. OPM recorded €0.4 million in R&D tax credits in the first half of 2025, down 52% compared to last year. The amount of R&D tax credits was reduced by the amount of public aid, the R&D expenditure base decreased, and the rules for collecting R&D tax credits changed (exclusion of technology watch patents, etc.). OPM's half-year net income thus stands at €9,846k, due to the integration of OPM-201 inventories at an estimated value of €13m. Cash position of €2.5m at June 30, 2025 As of June 30, 2025, OPM had cash reserves of €2.5 million, before receiving the Research Tax Credit, compared to €9.6 million (including the Research Tax Credit) as of June 30, 2024. The Research Tax Credit, amounting to €1.1 million, was received in July 2025. OPM has access to a maximum €5 million equity financing facility, which it has not yet used. The Company is in discussions with financial and pharmaceutical partners with the goal of signing a partnership agreement or raising funds. 2025 perspectives OPM has submitted its Phase 1b/2a protocol for the REVERT study evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 and is awaiting a response from Swiss ethics institutions. The first patient is expected to be enrolled by the end of 2025. Work on radioligands is continuing as part of the COMETE project. Partnership prospects or transfer mainly focus on the two most advanced molecules to date (OPM-101 and OPM-201). OPM's goal is to license or transfer OPM-101 at the end of Phase 2a to a pharmaceutical partner who will complete its development and commercialization. While we do not anticipate licensing or sales before the end of this phase in 2027, we are considering the possibility of a pharmaceutical partner taking a licensing option with the payment of an exclusivity fee, giving them first refusal on the results. For OPM-201, the objective is to find a partnership similar to the one we found with Servier in 2019 or a buyer. Availability of the 2025 half-year financial report The 2025 half-year financial report will be available on the company's website, within the legal deadline, before October 31, 2025. About Oncodesign Precision Medicine (OPM) Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers. OPM currently has two kinase inhibitors in clinical phase: OPM-101, intended for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, has demonstrated a significant therapeutic margin and absence of toxicity in its phase I healthy volunteers, with the start of phase 1b/2a in Oncology scheduled for early 2025. OPM-201, initially licensed to Servier and intended for the treatment of Parkinson's disease, completed its phase I trial in healthy volunteers at the end of 2024, and was reintegrated into OPM's portfolio. Both molecules come from the Nanocyclix ® technology platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. We now have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase. OPM's other two technology platforms are: OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, on which we have a partnership with Servier for the search for targets in pancreatic cancer, PROMETHE ® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, on which we are currently discussing partnerships with vectorization manufacturers. OPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in Dijon, at the heart of the university and hospital cluster, and employs 14 people. More info at: Forward-looking statements This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be identified by the use of words such as, without limitation, "believes", "anticipates", "expects", "projects", "plans", "seeks", "estimates", "may", "will" and "continue" and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable when they were made but which may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company's control. Consequently, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, the forward-looking statements, forecasts and estimates speak only as of the date of publication of this document. The Company disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which these statements, forecasts or estimates are based, except as required by French law.
News18
02-06-2025
- Business
- News18
French Firm Servier Drops Exclusive Deal For Selling High BP Drugs After Chemists' Pushback
Last Updated: After successful mediation by offline chemists, Servier promptly withdrew the agreement – which is seen as a positive step towards preserving the fairness of open trade practices. In a major development impacting the pharmaceutical distribution landscape in India, an Indian arm of French drugmaker Servier has officially withdrawn its exclusive distribution agreement for its anti-hypertensive product line, reverting to conventional distribution practices. The move comes after the apex lobby of offline chemists, All India Organisation of Chemists and Druggists (AIOCD), raised concerns, alleging the potential monopolistic implications of Servier's deal with Entero Healthcare, a supply chain specialist company. AIOCD represents more than 12 lakh chemists and distributors in India, pushing Servier to discontinue the arrangement of supplying certain products via Entero. The majority of the AIOCD's partners refused to sell the drugs sold by the French drugmaker. After facing industry pushback, in a letter dated May 26, 2025, Servier India informed its trade partners that it has 'discontinued exclusive distribution arrangement for anti-hypertensive range of products" with immediate effect. The letter has been seen by News18. This update follows a formal communication by AIOCD on May 28, addressing the issue. The letter detailed how many members of the organisation had expressed concerns over the exclusivity agreement, warning that it could lead to discriminatory trade practices, shortages in essential medications, and the formation of monopolistic structures within the pharmaceutical supply chain. AIOCD, in a letter, said that the organisation mediated with Servier to ensure a fair resolution. 'After successful mediation by AIOCD, the company has promptly withdrawn the said exclusive distribution agreement. This is a positive and encouraging step toward preserving the balance and fairness in our open trade practices," the letter read. The development is being seen as a victory for chemists and druggists across India, many of whom feared market distortions and reduced access to essential medicines due to exclusive arrangements. 'We have had fruitful discussions with AIOCD. Servier India is focused on improving patient access to our quality medicines. We will continue to engage constructively with all stakeholders," Aurelien Breton, managing director, Servier India told News18. Brenton told News18 that he is thankful to AIOCD 'for the constructive dialogue, which allowed us to resolve the matter amicably in the interest of the healthcare community and patients at large." 'Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world." Headquartered in France, Servier operates in around 140 countries. Sources close to the development told News18 that, 'Servier's management rushed the distributor appointment, with inadequate market assessment and due diligence. However, now, it has made right decision following the general rules of the Indian pharma trade market." First Published: June 02, 2025, 12:40 IST
Malaysian Reserve
28-05-2025
- Business
- Malaysian Reserve
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ — Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. 'Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs,' said Nicolas Garnier, Chief Patient Officer, Servier. 'This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies – underscoring the company's growing reputation and meaningful impact on patients worldwide. 'At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities,' said Wendy Poage, Vice President of the Patient Office at Servier. 'We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.' For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan
Yahoo
28-05-2025
- Business
- Yahoo
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier U.S. ranked #1 across several categories U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies. This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them. "Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs," said Nicolas Garnier, Chief Patient Officer, Servier. "This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D. Globally, Servier was also ranked among the top 10 companies - underscoring the company's growing reputation and meaningful impact on patients worldwide. "At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities," said Wendy Poage, Vice President of the Patient Office at Servier. "We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them." For more information on Servier Pharmaceuticals patient support services, please visit and About the Corporate Reputation of Pharma Survey 2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve. About Servier Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world. Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development. As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective. Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine. To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice. Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion. More information on our website : Follow us on social media : LinkedIn, Facebook, Twitter, Instagram Media Contact: Sara Noonan View original content to download multimedia: SOURCE Servier Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Citizen
13-05-2025
- Health
- The Citizen
Locals urged to check their blood pressure this May
Locals urged to check their blood pressure this May This May Measurement Month, health experts are sounding the alarm on hypertension (HTN), a condition that affects billions worldwide yet remains dangerously underdiagnosed and undertreated. Alarmingly, a recent study found that 74% of patients are unaware that they are at risk of hypertension or are unaware of their hypertension status. World Hypertension Day is observed on May 17. ALSO READ: Foundation calls for mental health support in gamblers HTN is the most significant risk factor for cardiovascular disease (in SA. With cardiovascular disease ranking among the top 10 causes of death worldwide, detecting and controlling blood pressure has never been more critical. Uncontrolled hypertension can lead to serious health complications, significantly increasing the risk of heart attack, stroke, kidney failure and heart failure. It's also linked to a higher likelihood of developing dementia and can drastically reduce overall quality of life. These consequences contribute to increased mortality and morbidity, underscoring the importance of early detection, treatment and management of high blood pressure. May Measurement Month A public health campaign, Because I Say So is part of a global blood pressure screening initiative, May Measurement Month. ALSO READ: Use suggestion boxes to raise concerns at healthcare facilities – City Now in its ninth year, this collaborative campaign was initiated in response to the hypertension health crisis. It is led by the International Society of Hypertension, in collaboration with the Southern African Hypertension Society and Servier, among other scientific societies. It is a public call for everyone to get their blood pressure (BP) checked. This non-invasive test takes five minutes, is free during May Measurement Month, and can help save lives. Professor Erika Jones, the president of the Southern African Hypertension Society, said, 'Hypertension is often called the 'silent killer' because it typically has no symptoms until significant damage has occurred. 'It is a leading cause of heart disease and stroke, accounting for nearly half of related deaths worldwide. Despite this, awareness, treatment and control remain alarmingly low.' The scale of the problem The statistics, as recorded in 2019, paint a concerning picture: • 4.06 billion adults were affected by high systolic blood pressure; • 1.3 billion adults (30-79 years) were affected by hypertension; • 10.8 million deaths were associated with raised blood pressure; • Approximately 60% of adults develop hypertension by 60 years of age; • Up to 90% of adults living to 80 are likely to develop hypertension; • Hypertension causes over 50% of heart disease, stroke and heart failure cases. SA faces an exceptionally high burden, with the South African Demographic and Health Survey (SADHS) reporting a hypertension prevalence of 46.0% in females and 44.0% in males above 18 years of age. Even more concerning, over 80% of people living with hypertension have uncontrolled blood pressure. This prevalence significantly exceeds the global average of 31.1%. ALSO READ: Local group walks to boost health The treatment gap A 'treatment cascade' exists for patients with hypertension. A report by the World Heart Federation (WHF), Roadmap for Hypertension, starts with those with high blood pressure, although many don't even know their status. Of those diagnosed, only a portion receive treatment, and fewer still achieve blood pressure control. Finally, patient adherence remains the biggest challenge. Effective prevention and detection of hypertension require a multi-faceted approach. This includes robust screening policies that include initial blood pressure screenings from the age of 18 and regular follow-ups and opportunistic screenings in various settings like workplaces, schools and community spaces. Population-wide interventions play a crucial role in prevention by promoting weight control through healthier diets (like the DASH diet), improving access to nutritious foods and implementing salt reduction strategies. 'Additionally, lifestyle interventions, such as adopting a balanced diet and increasing physical activity, are also essential in managing and reducing the risk of hypertension,' explained Jones. A WHF member survey across 46 countries showed 65% of the polled healthcare respondents reporting that their patients do not adhere to treatment plans, showing that even once the obstacles of detection and diagnosis are overcome, patients still struggle with maintaining their prescribed regimens. ALSO READ: Gauteng Health welcomes a new batch of counsellors Obstacles to prevention Despite knowing how to prevent and treat high blood pressure, many barriers stand in the way of success. These challenges affect patients and healthcare systems alike. For those diagnosed with hypertension, treatment brings its challenges – medication can be expensive, many people struggle to stay motivated for a condition with no obvious symptoms, there are cultural attitudes that sometimes discourage medical intervention, and daily pill routines can be complicated to maintain. ALSO READ: Make this month a healthy love story – Gauteng Health The healthcare systems face obstacles, too, including limited resources for widespread blood pressure screening; equipment shortages and inaccurate measurements; healthcare workers might have poor awareness or a misunderstanding of guidelines; and follow-up systems to monitor patient progress are often inadequate. With proper awareness of these challenges, patients and healthcare providers can work together to find practical solutions that make hypertension prevention and treatment more accessible for everyone. 'For more than 50 years, Servier has been committed to fighting high blood pressure – the 'silent killer' – that affects millions without warning. 'According to the World Health Organisation, this chronic illness claims over 11 million lives annually, making it humanity's largest epidemic. 'As non-communicable diseases like hypertension continue to rise, it solidifies the importance of collaborative public information campaigns like Because I Say So and May Measurement Month. 'We compel South Africans to take action and check their blood pressure. It has never been more crucial for public health,' says Virosha Deonarain, the medical manager at Servier. South Africans should go to their local pharmacies, clinics, or doctors to get tested for free in May. Find a participating pharmacy in your area and get the test today: At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
